Soligenix, Inc. 0A6I.L Stock
Soligenix, Inc. Price Chart
Soligenix, Inc. 0A6I.L Financial and Trading Overview
Soligenix, Inc. stock price | 0.37 USD |
Previous Close | 0.72 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 14.55 USD |
Volume | 24.7K USD |
Avg. Volume | 3.97K USD |
Market Cap | N/A |
Beta (5Y Monthly) | 1.766901 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.349 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0A6I.L Valuation Measures
Enterprise Value | 4.76M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 4.678 |
Enterprise Value/EBITDA | -0.391 |
Trading Information
Soligenix, Inc. Stock Price History
Beta (5Y Monthly) | 1.766901 |
52-Week Change | -91.37% |
S&P500 52-Week Change | 20.43% |
52 Week High | 14.55 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 5.1 USD |
200-Day Moving Average | 6.04 USD |
0A6I.L Share Statistics
Avg. Volume (3 month) | 3.97K USD |
Avg. Daily Volume (10-Days) | 834 USD |
Shares Outstanding | N/A |
Float | 8.08M |
Short Ratio | N/A |
% Held by Insiders | 0.36% |
% Held by Institutions | 7.18% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | 0.066667:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1198.12% |
Gross Margin | 32.74% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -43.84% |
Return on Equity (ttm) | -656.49% |
Income Statement
Revenue (ttm) | 1.02M USD |
Revenue Per Share (ttm) | 0.35 USD |
Quarterly Revenue Growth (yoy) | 36.79% |
Gross Profit (ttm) | N/A |
EBITDA | -12186842 USD |
Net Income Avi to Common (ttm) | -10495427 USD |
Diluted EPS (ttm) | -0.349 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 10.27M USD |
Total Cash Per Share (mrq) | 1.27 USD |
Total Debt (mrq) | 9.22M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.942 |
Book Value Per Share (mrq) | -1.156 |
Cash Flow Statement
Operating Cash Flow (ttm) | -11576431 USD |
Levered Free Cash Flow (ttm) | -9151346 USD |
Profile of Soligenix, Inc.
Country | United Kingdom |
State | NJ |
City | Princeton |
Address | 29 Emmons Drive |
ZIP | 08540 |
Phone | 609 538 8200 |
Website | https://www.soligenix.com |
Industry | |
Sector(s) | |
Full Time Employees | 13 |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Q&A For Soligenix, Inc. Stock
What is a current 0A6I.L stock price?
Soligenix, Inc. 0A6I.L stock price today per share is 0.37 USD.
How to purchase Soligenix, Inc. stock?
You can buy 0A6I.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Soligenix, Inc.?
The stock symbol or ticker of Soligenix, Inc. is 0A6I.L.
How many shares does Soligenix, Inc. have in circulation?
The max supply of Soligenix, Inc. shares is 0.
What is Soligenix, Inc. Price to Earnings Ratio (PE Ratio)?
Soligenix, Inc. PE Ratio is now.
What was Soligenix, Inc. earnings per share over the trailing 12 months (TTM)?
Soligenix, Inc. EPS is -0.349 USD over the trailing 12 months.